Therapeutic options for human brucellosis

References

• Capasso L. Bacteria in two-millennia-old cheese, and related epizoonoses in Roman populations. J. Infect.45(2), 122–127 (2002).
   PubMedGoogle Scholar
• Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N. Engl. J. Med.352, 2325–2336 (2005).
   PubMed Web of Science ®Google Scholar
• Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect. Dis.6(2), 91–99 (2006).
   PubMed Web of Science ®Google Scholar
• Corbel MJ. Brucellosis: an overview. Emerg. Infect. Dis.3, 213–221 (1997).
   PubMed Web of Science ®Google Scholar
• Jahans K L, Foster G, Broughton ES. The characterization of Brucella strains isolated from marine mammals. Vet. Microbiol.57, 373–382 (1997).
   PubMedGoogle Scholar
• Ko J, Splitter GA. Molecular host–pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans. Clin. Microbiol. Rev.6(1), 65–78 (2003).
   Google Scholar
• Cloeckaert A, Verger JM, Grayon M et al. Classification of Brucella spp. isolated from marine mammals by DNA polymorphism at the omp2 locus. Microbes Infect.3(9), 729–738 (2001).
   PubMedGoogle Scholar
• Sohn AH, Probert WS, Glaser CA et al. Human neurobrucellosis with intracerebral granuloma caused by a marine mammal Brucella spp. Emerg. Infect. Dis.9, 485–488 (2003).
   PubMed Web of Science ®Google Scholar
• Brew SD, Perrett LL, Stack JA, MacMillan AP, Staunton NJ. Human exposure to Brucella recovered from a sea mammal. Vet. Rec.144(17), 483 (1999).
   PubMedGoogle Scholar
• Kaufmann AF, Meltzer MI, Schmid GP. The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable? Emerg. Infect. Dis.3, 83–94 (1997).
   Google Scholar
• Palanduz A, Palanduz S, Guler K, Guler N. Brucellosis in a mother and her young infant: probable transmission by breast milk. Int. J. Infect. Dis.4(1), 55–56 (2000).
   PubMedGoogle Scholar
• Ruben B, Band JD, Wong P, Colville J. Person-to-person transmission of Brucella melitensis. Lancet337(8732), 14–15 (1991).
   PubMed Web of Science ®Google Scholar
• Lindberg J, Larsson P. Transmission of Brucella melitensis. Lancet337(8745), 848–849 (1991).
   PubMedGoogle Scholar
• Poulou A, Markou F, Xipolitos I, Skandalakis PN. A rare case of Brucella melitensis infection in an obstetrician during the delivery of a transplacentally infected infant. J. Infect.53(1), e39–e41 (2006).
   Google Scholar
• Detilleux PG, Deyoe BL, Cheville NF. Effect of endocytic and metabolic inhibitors on the internalization and intracellular growth of Brucella abortus in Vero cells. Am. J. Vet. Res.52, 1658–1664 (1991).
   PubMedGoogle Scholar
• Gross A, Terraza A, Ouahrani-Bettache S, Liautard JP, Dornand J. In vitroBrucella suis infection prevents the programmed cell death of human monocytic cells. Infect. Immun.68(1), 342–351 (2000).
   PubMed Web of Science ®Google Scholar
• Pizarro-Cerda J, Moreno E, Sanguedolce V, Mege JL, Gorvel JP. Virulent Brucella abortus prevents lysosome fusion and is distributed within autophagosome-like compartments. Infect. Immun.66, 2387–2392 (1998).
   PubMedGoogle Scholar
• Bravo MJ, de Dios Colmenero J, Alonso A, Caballero A. Polymorphisms of the interferon γ and interleukin 10 genes in human brucellosis. Eur. J. Immunogenet.30(6), 433–435 (2003).
   PubMedGoogle Scholar
• Kokoglu OF, Hosoglu S, Geyik MF et al. Clinical and laboratory features of brucellosis in two university hospitals in Southeast Turkey. Trop. Doct.36(1), 49–51 (2006).
   PubMed Web of Science ®Google Scholar
• Ayatollahi J. Epidemiological, clinical, diagnostic and therapeutic survey of 686 cases of brucellosis. Ann. Saudi Med.24(5) 398–399 (2004).
   PubMedGoogle Scholar
• Mousa AM, Muhtaseb SA, Reddy RR, Senthilselvan A, Al-Mudallal DS, Marafie AA. The high rate of prevalence of CT-detected basal ganglia calcification in neuropsychiatric (CNS) brucellosis. Acta Neurol. Scand.76(6), 448–56 (1987).
   PubMedGoogle Scholar
• Al-Aska AK. Gastrointestinal manifestations of brucellosis in Saudi Arabian patients. Trop. Gastroenterol.10(4), 217–219 (1989).
   PubMedGoogle Scholar
• Kochar DK, Sharma BV, Gupta S, Jain R, Gauri LA, Srivastava T. Pulmonary manifestations in brucellosis: a report on seven cases from Bikaner (north-west India). J Assoc Physicians India51, 33–36 (2003).
   PubMedGoogle Scholar
• Solera J, Martínez-Alfero E, Espinosa A, Castillejos ML, Geijo P, Rodríguez-Zapata M. Multivariate model for predicting relapse in human brucellosis. J. Infect.36, 85–92 (1998).
   PubMed Web of Science ®Google Scholar
• Ariza J, Corredoira J, Pallares R et al. Characteristics of and risk factors for relapse of brucellosis in humans. Clin. Infect. Dis.20(5), 1241–1249 (1995).
   PubMed Web of Science ®Google Scholar
• Casas J, Portal Y, J Llosá, Leiva J, Navarro JM, de la Rosa M. Detection of Brucella by an automatic hemoculture system: Bact/Alert. Enferm. Infecc. Microbiol. Clin.12, 497–500 (1994).
   PubMedGoogle Scholar
• Ruiz J, Lorente I, Pérez J, Simarro E, Martínez-Campos L. Diagnosis of brucellosis by using blood cultures. J. Clin. Microbiol.35, 2417–2418 (1997).
   PubMedGoogle Scholar
• Roiz MP, Peralta FG, Valle R, Arjona R. Microbiological diagnosis of brucellosis. 36(6), 1819 (1998).
   Google Scholar
• Almuneef M, Memish ZA. Persistence of Brucella antibodies after successful treatment of acute brucellosis in an area of endemicity. J. Clin. Microbiol.40(6), 2313 (2002).
   PubMed Web of Science ®Google Scholar
• Fadeel MA, Wasfy MO, Pimentel G, Klena JD, Mahoney FJ, Hajjeh RA. Rapid enzyme-linked immunosorbent assay for the diagnosis of human brucellosis in surveillance and clinical settings in Egypt. Saudi Med. J.27(7), 975–981 (2006).
   PubMedGoogle Scholar
• Clavijo E, Diaz R, Anguita A, Garcia A, Pinedo A, Smits HL. Comparison of a dipstick assay for detection of Brucella-specific immunoglobulin M antibodies with other tests for serodiagnosis of human brucellosis. Clin. Diagn. Lab. Immunol.10(4), 612–615 (2003)
   PubMedGoogle Scholar
• Casao MA, Smits HL, Navarro E, Solera J. Clinical utility of a dipstick assay in patients with brucellosis: correlation with the period of evolution of the disease. Clin. Microbiol. Infect.9(4), 301–305 (2003).
   PubMedGoogle Scholar
• Lucero NE, Escobar GI, Ayala SM, Silva Paulo P, Nielsen K. Fluorescence polarization assay for diagnosis of human brucellosis. J. Med. Microbiol.52(Pt 10), 883–887 (2003).
   PubMed Web of Science ®Google Scholar
• Young EJ. An overview of human brucellosis. Clin. Infect. Dis.21(2), 283–289 (1995).
   PubMed Web of Science ®Google Scholar
• Kattar MM, Zalloua PA, Araj GF, et al. Development and evaluation of real-time polymerase chain reaction assays on whole blood and paraffin-embedded tissues for rapid diagnosis of human brucellosis. Diagn. Microbiol. Infect. Dis.59(1), 23–32 (2007).
   PubMedGoogle Scholar
• Mitka S, Anetakis C, Souliou E, Diza E, Kansouzidou A. Evaluation of different PCR assays for early detection of acute and relapsing brucellosis in humans in comparison with conventional methods. J. Clin. Microbiol.45(4), 1211–1218 (2007).
   PubMed Web of Science ®Google Scholar
• Maas KS, Méndez M, Zavaleta M, et al. Evaluation of brucellosis by PCR and persistence after treatment in patients returning to the hospital for follow-up. Am. J. Trop. Med. Hyg.76(4), 698–702 (2007).
   PubMed Web of Science ®Google Scholar
• Navarro E, Segura JC, Castano MJ, Solera J. Use of real-time quantitative polymerase chain reaction to monitor the evolution of Brucella melitensis DNA load during therapy and post-therapy follow-up in patients with brucellosis. Clin. Infect. Dis.42(9), 1266–1273 (2006).
   PubMed Web of Science ®Google Scholar
• Solera J, Espinosa A, Martinez-Alfaro E et al. Treatment of human brucellosis with doxycycline and gentamicin. Antimicrob. Agents Chemother.41, 80–84 (1997).
   PubMed Web of Science ®Google Scholar
• Abramson O, Abu-Rashid M, Gorodischer R, Yagupsky P. Failure of short antimicrobial treatments for human brucellosis. Antimicrob. Agents Chemother.41, 1621–1622 (1997).
   PubMed Web of Science ®Google Scholar
• Llorens-Terol J, Busquets RM. Brucellosis treated with rifampin. Arch. Dis. Child.55, 486–488 (1980).
   PubMed Web of Science ®Google Scholar
• Lubani MM, Dudin KI, Sharda DC et al. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr. Infect. Dis. J.8, 75–78 (1989).
   PubMed Web of Science ®Google Scholar
• Lang R, Raz R, Sacks T, Shapiro M. Failure of prolonged treatment with ciprofloxacin in acute infections due to Brucella melitensis. J. Antimicrob. Chemother.26, 841–846 (1990).
   PubMed Web of Science ®Google Scholar
• Al Sibai MB, Halim MA, el Shaker MM, Khan BA, Qadri SM. Efficacy of ciprofloxacin for treatment of Brucella melitensis infections. Antimicrob. Agents Chemother.36, 150–152 (1992).
   PubMedGoogle Scholar
• Doganay M, Aygen B. Use of ciprofloxacin in the treatment of brucellosis. Eur. J. Clin. Microbiol. Infect. Dis.11, 74–75 (1992).
   PubMed Web of Science ®Google Scholar
• Joint FAO/WHO Expert Committee on Brucellosis. WHO Tech. Rep. Ser.740, 1–132 (1986).
   Google Scholar
• Acocella G, Bertrand A, Beytout J et al. Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study. J. Antimicrob. Chemother.23, 433–439 (1989).
   PubMed Web of Science ®Google Scholar
• Ariza J, Gudiol F, Pallares R et al. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. Ann. Intern. Med.117, 25–30 (1992).
   PubMed Web of Science ®Google Scholar
• Montejo JM, Alberola I, Glez-Zarate P et al. Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis. Clin. Infect. Dis.16, 671–676 (1993).
   PubMed Web of Science ®Google Scholar
• Solera J, Martinez-Alfaro E, Saez L. Meta-analysis of the efficacy of the combination of rifampicin and doxycycline in the treatment of human brucellosis. Med. Clin. (Barc.)102, 731–738 (1994).
   PubMedGoogle Scholar
• Solera J, Rodriguez-Zapata M, Geijo P et al. Doxycycline–rifampin versus doxycycline–streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas. Antimicrob. Agents Chemother.39, 2061–2067 (1995).
   PubMed Web of Science ®Google Scholar
• Ariza J, Gudiol F, Pallares R, Rufi G, Fernandez-Viladrich P. Comparative trial of rifampin–doxycycline versus tetracycline–streptomycin in the therapy of human brucellosis. Antimicrob. Agents Chemother.28, 548–551 (1985).
   PubMed Web of Science ®Google Scholar
• Colmenero JD, Fernandez-Gallardo LC, Agundez JA, Sedeno J, Benitez J, Valverde E. Possible implications of doxycycline–rifampin interaction for treatment of brucellosis. Antimicrob. Agents Chemother.38, 2798–2802 (1994).
   PubMed Web of Science ®Google Scholar
• Akova M, Uzun O, Akalin HE, Hayran M, Unal S, Gur D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin–rifampin versus doxycycline–rifampin. Antimicrob. Agents Chemother.37, 1831–1834 (1993).
   PubMed Web of Science ®Google Scholar
• Karabay O, Sencan I, Kayas D, Sahin I. Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial. BMC Infect. Dis.4, 18 (2004).
   PubMedGoogle Scholar
• Saltoglu N, Tasova Y, Inal AS, Seki T, Aksu HS. Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis. Saudi Med. J.23, 921–924 (2002).
   PubMedGoogle Scholar
• Ersoy Y, Sonmez E, Tevfik MR, But AD. Comparison of three different combination therapies in the treatment of human brucellosis. Trop. Doct.35(4), 210–212 (2005).
   PubMedGoogle Scholar
• Kalo T, Novi S, Nushi A, Dedja S. Ciprofloxacin plus doxycycline versus rifampicin plus doxycycline in the treatment of acute brucellosis. Med. Mal. Infect.26, 587–589 (1996).
   Google Scholar
• Falagas ME, Bliziotis IA. Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies. Antimicrob. Agents Chemother.50(1), 22–33 (2006).
   PubMed Web of Science ®Google Scholar
• Solera J, Medrano F, Rodriguez M, et al. A comparative therapeutic and multicenter trial of rifampin and doxycycline versus streptomycin and doxycycline in human brucellosis. Med. Clin. (Barc.)96, 649–653 (1991).
   PubMedGoogle Scholar
• Lulu AR, Araj GF, Khateeb MI. Human brucellosis in Kuwait: a prospective study of 400 cases. Q. J. Med.249, 39–54 (1988).
   Google Scholar
• Hasanjani Roushan MR, Mohraz M, Hajiahmadi M, Ramzani A, Valayati AA. Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans. Clin. Infect. Dis.42(8), 1075–1080 (2006).
   PubMed Web of Science ®Google Scholar
• Roushan MR, Gangi SM, Ahmadi SA. Comparison of the efficacy of two months of treatment with co-trimoxasol plus doxycycline vs. co-trimoxasol plus rifampin in brucellosis. Swiss Med. Wkly134, 564–568 (2004).
   PubMed Web of Science ®Google Scholar
• Solera J, Martinez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs53(2), 245–256 (1997).
   PubMed Web of Science ®Google Scholar
• Farid Z, Miale A Jr, Omar MS, Van Peenen PF. Antibiotic treatment of acute brucellosis caused by Brucella melitensis. J. Trop. Med. Hyg.64, 157–163 (1961).
   PubMed Web of Science ®Google Scholar
• Hall HW. Modern chemotherapy for brucellosis in humans. Rev Infect Dis.12, 1060–1099 (1990).
   PubMedGoogle Scholar
• Solera J, Beato JL, Martinez-Alfaro E, Segura JC, de Tomas E; Grupo de Estudio de Castilla la Mancha de Enfermedades Infecciosas Group. Azithromycin and gentamicin therapy for the treatment of humans with brucellosis. Clin. Infect. Dis.32(3), 506–509 (2001).
   PubMedGoogle Scholar
• Al-Eissa YA, Kambal AM, al-Nasser MN, al-Habib SA, al-Fawaz IM, al-Zamil FA. Childhood brucellosis: a study of 102 cases. Pediatr. Infect. Dis. J.9, 74–79 (1990).
   PubMed Web of Science ®Google Scholar
• Khan MY, Mah MW, Memish ZA. Brucellosis in pregnant women. Clin. Infect. Dis.32(8), 1172–1177 (2001).
   PubMed Web of Science ®Google Scholar
• Khuri-Bulos NA, Daoud AH, Azab SM. Treatment of childhood brucellosis: results of a prospective trial on 113 children. Pediatr. Infect. Dis. J.12, 377–381 (1993).
   PubMed Web of Science ®Google Scholar
• Shaalan MA, Memish ZA, Mahmoud SA et al. Brucellosis in children: clinical observations in 115 cases. Int. J. Infect. Dis.6, 182–186 (2002).
   PubMedGoogle Scholar
• Almuneef M, Memish ZA, Al Shaalan M, Al Banyan E, Al-Alola S, Balkhy HH. Brucella melitensis bacteremia in children: review of 62 cases. J. Chemother.15(1), 76–80 (2003).
   PubMed Web of Science ®Google Scholar
• Yuca SA, Ceylan A, Caksen H, Kirimi E, Yilmaz C, Bay A. Comparison of various treatments in childhood brucellosis. J. Pediatr. Infect. Dis.1, 225–229 (2006).
   Google Scholar
• Roushan MR, Mohraz M, Janmohammadi N, Hajiahmadi M. Efficacy of cotrimoxazole and rifampin for 6 or 8 weeks of therapy in childhood brucellosis. Pediatr. Infect. Dis. J.25(6), 544–545 (2006).
   PubMedGoogle Scholar
• Hendricks MK, Perez EM, Burger PJ, Mouton PA. Brucellosis in childhood in the Western Cape. S. Afr. Med. J.85, 176–178 (1995).
   PubMedGoogle Scholar
• Tsolia M, Drakonaki S, Messaritaki A et al. Clinical features, complications and treatment outcome of childhood brucellosis in central Greece. J. Infect.44, 257–262 (2002).
   PubMed Web of Science ®Google Scholar
• Solera J, Geijo P, Largo J et al. A randomized, double-blind study to assess the optimal duration of doxycycline treatment for human brucellosis. Clin. Infect. Dis.39(12), 1776–1782 (2004).
   PubMed Web of Science ®Google Scholar
• Vajramani GV, Nagmoti MB, Patil CS. Neurobrucellosis presenting as an intra-medullary spinal cord abscess. Ann. Clin. Microbiol. Antimicrob.4, 14 (1987).
   Google Scholar
• Bashir R, Al-Kawi MZ, Harder EJ, Jinkins J. Nervous system brucellosis: diagnosis and treatment. Neurology35, 1576–1581 (1985).
   PubMed Web of Science ®Google Scholar
• Hernandez-Perez MA, Anciones Rodriguez B, Garcia AF, Diez-Tejedor E, Barreiro Tella PB. Treatment of nervous system brucellosis with rifampicin and doxycycline. Neurology36, 1408–1409 (1986).
   PubMedGoogle Scholar
• Pascual J, Combarros O, Polo JM, Berciano J. Localized CNS brucellosis: report of 7 cases. Acta Neurol. Scand.78(4), 282–289(1988).
   PubMed Web of Science ®Google Scholar
• Bouza E, Garcia de la Torre M, Parras F, Guerrero A, Rodriguez-Creixems M, Gobernado J. Brucellar meningitis. Rev. Infect. Dis.9(4), 810–822 (1987).
   PubMedGoogle Scholar
• McLean DR, Russell N, Khan MY. Neurobrucellosis: clinical and therapeutic features. Clin. Infect. Dis.15(4), 582–90 (1992).
   PubMed Web of Science ®Google Scholar
• Al Dahouk S, Schneider T, Jansen A et al.Brucella endocarditis in prosthetic valves. Can. J. Cardiol.22(11), 971–4 (2006).
   PubMedGoogle Scholar
• Mert A, Kocak F, Ozaras R, et al. The role of antibiotic treatment alone for the management of Brucella endocarditis in adults: a case report and literature review. Ann. Thorac. Cardiovasc. Surg.8, 381–385 (2002).
   PubMedGoogle Scholar
• Al Dahouk S, Tomaso H, Nockler K, Neubauer H, Frangoulidis D. Laboratory-based diagnosis of brucellosis: a review of the literature. Part I: techniques for direct detection and identification of Brucella spp. Clin. Lab.49, 487–505 (2003).
   PubMedGoogle Scholar
• Probert WS, Schrader KN, Khuong NY, Bystrom SL, Graves MH. Real-time multiplex PCR assay for detection of Brucella spp, B. abortus and B. melitensis. J. Clin. Microbiol.42, 1290–1293 (2004).
   PubMed Web of Science ®Google Scholar
• Tasbakan MI, Yamazhan T, Arda B, et al. Tissue culture positive prosthetic aortic valve Brucella endocarditis. Ir. J. Med. Sci.175(2), 84 (2006).
   PubMedGoogle Scholar
• Cohen N, Golik A, Alon I et al. Conservative treatment for Brucella endocarditis. Clin. Cardiol.20, 291–294 (1997).
   PubMedGoogle Scholar
• El Miedany YM, El Gaafary M, Baddour M, Ahmed I. Human brucellosis: do we need to revise our therapeutic policy? J. Rheumatol.30(12), 2666–2672 (2003).
   PubMedGoogle Scholar
• Alp E, Koc RK, Durak AC et al. Doxycycline plus streptomycin versus ciprofloxacin plus rifampicin in spinal brucellosis [ISRCTN31053647]. BMC Infect. Dis.6(1), 72 (2006).
   PubMedGoogle Scholar
• Lecaroz MC, Blanco-Prieto MJ, Campanero MA, Salman H, Gamazo C. Poly (d,l-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice. Antimicrob. Agents Chemother.51(4), 1185–1190 (2007).
   PubMed Web of Science ®Google Scholar
• Dizbay M, Kilic S, Hizel K, Arman D. Tigecycline: its potential for treatment of brucellosis. Scand. J. Infect. Dis.39(5), 432–434 (2007).
   PubMed Web of Science ®Google Scholar
• Turan H, Arslan H, Azap OK, Serefhanolu K, Uncu H. In vitro antibacterial activity of tigecycline in comparison with doxycycline, ciprofloxacin and rifampicin against Brucella spp. Int. J. Antimicrob. Agents.30(2), 186–187 (2007).
   PubMed Web of Science ®Google Scholar
• Pappas G, Papadimitriou P, Christou L, Akritidis N. Future trends in human brucellosis treatment. Expert Opin. Investig. Drugs.15(10), 1141–1149 (2006).
   PubMed Web of Science ®Google Scholar
• Cassataro J, Pasquevich KA, Estein SM et al. A DNA vaccine coding for the quimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine.25(32), 5958–5967 (2007).
   PubMed Web of Science ®Google Scholar
• Commander NJ, Spencer SA, Wren BW, MacMillan AP. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Vaccine.25(1), 43–54 (2007).
   PubMed Web of Science ®Google Scholar
• Yang X, Walters N, Robison A, Trunkle T, Pascual DW. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. Vaccine.25(12), 2261–2268 (2007).
   PubMed Web of Science ®Google Scholar
• Irmak H, Buzgan T, Karahocagil MK, Evirgen O, Akdeniz H, Demiröz AP. The effect of levamisole combined with the classical treatment in chronic brucellosis. Tohoku J. Exp. Med.201(4), 221–228 (2003).
   PubMed Web of Science ®Google Scholar
• Dizer U, Hayat L, Beker CM, Gorenek L, Ozguven V, Pahsa A. The effect of the doxycycline–rifampicin and levamisole combination on lymphocyte subgroups and functions of phagocytic cells in patients with chronic brucellosis. Chemotherapy.51(1), 27–31 (2005).
   PubMed Web of Science ®Google Scholar
• Printzis S, Raptopoulou-Gigi M, Orphanou-Koumerkeridou H, Lagre F, Goulis G. Immunotherapy in chronic brucellosis. Effect of levamisole and interferon; mechanisms of action and clinical value. Immunopharmacol. Immunotoxicol.16, 679–693 (1994).
   PubMed Web of Science ®Google Scholar
• Al-Hajjaj MS, Al-Kassimi FA, Al-Mobeireek AF, Alzeer AH. Progressive rise of Mycobacterium tuberculosis resistance to rifampicin and streptomycin in Riyadh, Saudi Arabia. Respirology6(4), 317–322 (2001).
   PubMedGoogle Scholar
• Ariza J, Bosilkovski M, Cascio A et al. International Society of Chemotherapy; Institute of Continuing Medical Education of Ioannina. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med.4(12), e317 (2007).
   PubMed Web of Science ®Google Scholar